BIO BIO-RAD LABORATORIES, INC.

NYSE bio-rad.com


$ 331.57 $ 9.37 (2.91 %)    

Tuesday, 21-Oct-2025 15:59:53 EDT
QQQ $ 610.81 $ 0.00 (0 %)
DIA $ 469.22 $ 0.00 (0 %)
SPY $ 671.76 $ 0.00 (0 %)
TLT $ 92.01 $ 0.00 (0 %)
GLD $ 374.26 $ 0.00 (0 %)
$ 331.27
$ 323.75
$ 279.00 x 1
$ 339.51 x 2
-- - --
$ 211.43 - $ 387.99
375,599
na
8.96B
$ 1.03
$ 28.09
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-02-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-16-2024 12-31-2023 10-K
8 10-27-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 02-17-2023 12-31-2022 10-K
12 10-28-2022 09-30-2022 10-Q
13 07-29-2022 06-30-2022 10-Q
14 04-29-2022 03-31-2022 10-Q
15 02-11-2022 12-31-2021 10-K
16 10-29-2021 09-30-2021 10-Q
17 07-30-2021 06-30-2021 10-Q
18 04-30-2021 03-31-2021 10-Q
19 02-16-2021 12-31-2020 10-K
20 10-30-2020 09-30-2020 10-Q
21 07-31-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 11-01-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-05-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 04-16-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-07-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-01-2017 12-31-2016 10-K
36 11-02-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-maintains-outperform-on-bio-rad-laboratories-raises-price-target-to-409

RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target f...

 wells-fargo-maintains-equal-weight-on-bio-rad-laboratories-raises-price-target-to-265

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price tar...

 bio-rad-laboratories-narrows-fy2025-sales-guidance-from-2541b-2606b-to-2567b-2593b-vs-2520b-est

Bio-Rad Laboratories (NYSE:BIO) narrows FY2025 sales outlook from $2.541 billion-$2.606 billion to $2.567 billion-$2.593 billio...

 bio-rad-laboratories-q2-adj-eps-261-beats-176-estimate-sales-651600m-beat-615110m-estimate

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.61 per share which beat the analyst consensus estimate of $1....

 ubs-maintains-buy-on-bio-rad-laboratories-lowers-price-target-to-310

UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $355 to $310.

 citigroup-maintains-buy-on-bio-rad-laboratories-lowers-price-target-to-350

Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $40...

 rbc-capital-maintains-outperform-on-bio-rad-laboratories-lowers-price-target-to-392

RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and lowers the price target f...

 bio-rad-laboratories-q1-adj-eps-254-beats-181-estimate-sales-58540m-beat-57326m-estimate

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.54 per share which beat the analyst consensus estimate of $1....

 wells-fargo-maintains-equal-weight-on-bio-rad-laboratories-lowers-price-target-to-270

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price tar...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION